Varenicline Tablet, Film Coated
Product Images NDC 50090-7182

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Varenicline (NDC 50090-7182). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907182)

The packaging label for varenicline 1 mg film-coated tablets by A-S Medication Solutions. It includes the NDC 50090-7182-0, product number 7225-0, and states each tablet contains 1.71 mg varenicline tartrate equivalent to 1 mg varenicline free base. The label also instructs storage at 70 degrees Fahrenheit and protection from light. The package contains 56 tablets.*

FDA Label Image

Var-fig-1 (Var Fig 1)

Bar chart showing percentage outcomes from four different clinical studies (Study 2, 3, 4, and 5) comparing varenicline at various doses (0.5 mg BID, 10 mg BID, Flexible dosing) and bupropion SR 150 mg BID against placebo. Each study presents multiple bars representing different treatments with error bars indicating variability.*

FDA Label Image

Var-fig-2 (Var Fig 2)

A bar chart comparing percentage values across four clinical studies (Study 2, Study 3, Study 4, Study 5) for varenicline at doses of 0.5 mg and 1.0 mg twice daily (BID), bupropion 150 mg BID, and placebo. Each study group has bars representing treatment and placebo percentages with error bars showing variation.*

FDA Label Image

Var01 (Var01)

Chemical structure diagram of varenicline tartrate, illustrating the active ingredient's molecular components including the tartrate moiety and varenicline core structure as presented in the product data.*

FDA Label Image

Var04 (Var04)

A line chart comparing the percentage of continuous abstinent patients over weeks of nontreatment follow-up between Varenicline Tablets 1.0 mg BID and placebo. The x-axis shows follow-up duration in weeks, and the y-axis represents the percentage of continuous abstinent individuals. Two lines show a decline in abstinence over time, with varenicline having a higher percentage consistently than placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.